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With his proverbial thoughts on the ‘Perpetual Flux’ (Πάντα ῥεῖ :
panta rhei), Heraclitus from Ephesus [1] expressed, around the
year 500 BC, a universal rule that is also applicable to healthcare,
including thoracic and cardio-vascular surgery. Some of the
drivers for change in our ﬁeld today that are most frequently
raised are demographic changes and cost issues. Indeed, there is
no easy solution to the resulting dilemma due to rising caseloads
in combination with more fragile patients. However, it may be
shortsighted to focus on this issue alone when the standard
answer is to do more for less.
It must be worth considering that there may be other routes of
development for thoracic and cardio-vascular surgery that deserve
to be explored. There are many recommendations for shaping the
future, including the one given in the Bible [2]: ‘seek and you will
ﬁnd’. Alternatively, waiting for serendipity (ﬁnding by not searching)
with an unlimited timeline is an option. But, the combination of
both approaches is more promising, as suggested by Thomas Alva
Edison [3]: ‘Pretty much everything will come to him who hustles
while he waits’. Those who wonder what ‘hustling’ means in (t)his
context may like to consider a second Edison quote: ‘Personally, I
enjoy working about 18 h a day. Besides the short catnaps I take
each day, I average about four to ﬁve hours of sleep per night’. A
statement obviously incompatible with the European Working
Time Directive [4] and its 48 h default right to work in order to
protect the people’s health and safety. Obviously, a worker’s safety,
i.e. a doctor’s, is put above the patient’s here. Indeed, this is an
interesting position coming from our cash-strapped governments.
In looking for alternatives, the most important question to ask
is what to focus on in our research and development efforts, in
order to make a difference. Fortunately enough, I got some
inspiration from one of my late uncles, Albin Mayr, from
Innsbruck, Austria. He claimed that the most beautiful tracks for
driving are there, where it is forbidden to drive. As a boy, I was
extremely impressed by that statement, because I was sure, that
he was speaking from experience. Despite this, I cannot tell until
today, whether this experience was gained before or after the
introduction of the regulations, i.e. the trafﬁc ban.
This being said, I suggest visiting some forbidden fruit in the ﬁeld
of thoracic and cardio-vascular surgery hanging at various levels by
looking at the following with a somewhat structured approach:
(i) Contraindications of yesterday
(ii) Indications of today
(iii) Contraindications of today
(iv) Indications of tomorrow
When I was a student, bleeding gastric ulcers were primarily
treated with iced water, and if that did not work, a
Sengstaken–Blakemeore balloon was inserted, usually not an
easy task in blood-vomiting patients. If that was not effective
either, open surgery was performed for a direct suture of
the bleeding gastric vessel, excision of the ulcer, and partial
gastrectomy in more severe cases [5]. For some of the gas-
trectomy procedures, the so-called PETZ apparatus was used,
an ingenious stapling device invented in 1921 by Aldar von
Petz, a Hungarian surgeon [6]. In those days, an essential
lesson I learned was that those hand-loaded staples of the
staple instruments worked immediately in about 50% of
cases. In the other half, some staples would fall in the open
peritoneal cavity and/or some staples would not close in a
reliable fashion. By the time reliable staplers were devel-
oped, i.e. in the 1980s [7], gastric resection for bleeding
ulcers had disappeared several times. The ﬁrst time, it was
replaced by vagotomy and its supraselective variations, the
second time by efﬁcient medication including proton-pump
inhibitors for the blocking of acid production and the third
time by the eradication of Helicobacter pylori. Today, more
than 100 years after its inception, very efﬁcient and even
motorized staplers, that were originally developed and indi-
cated for laparoscopic abdominal surgery are used frequently
for the removal of left atrial appendages (Fig. 1) in minimally
invasive surgery for the treatment of atrial ﬁbrillation [8], a
treatment option that was offered for a long time in com-
bination with other open heart procedures and contraindi-
cated in lone atrial ﬁbrillation.
Another interesting observation can be made for the treat-
ment of traumatic fractures of the extremities. For a long
time, ‘stabilization’ of the fracture by extensions bound the
patient to the hospital bed and had him ﬁght against many
kilos for weeks and months, a condition to be followed by
another period with casts made from plaster. Immobilization
was the rule! This changed completely with the advent of
inner stabilization of the fractured bone by nails, plates and
screws [9], allowing for early mobilization of the patient out of
the bed, out of the room, out of the ward and out of the
hospital. On top of the reduction in muscle loss and improved
comfort for the patient, this new approach indicating early
mobilization also markedly reduced the risk of thrombo-
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embolic complications [10], a major cardio-vascular threat with
often fatal consequences.
TERMINAL HEART FAILURE
A fairly similar observation can be made for mechanical circula-
tory support, where the ﬁrst surviving patients [11] had their
chests kept open for the connection of para-corporeal ventricu-
lar assist devices (VADs), and were therefore not only tied to
heavy drivers with back-up and monitoring equipment, but also
to the bed. As a matter of fact, it was sometimes contraindicated
to turn the patients on their side, with all the unpleasant impli-
cations for the skin, especially if vaso-constricting drugs had to
be used in addition. Indeed, immobilization was the rule. With
the advent of implantable VADs (Fig. 2A) with portable drivers,
the picture changed completely. Suddenly, patients could be
moved out of the bed, out of the intensive care unit, out of the
ward and again out of the hospital [12]. Mobilization that was
previously contraindicated became very much indicated. There
were still some limitations due to the skin-crossing driver and
vent lines, but with the development of transcutaneous energy
transfer systems such as the Lion Heart (Fig. 2B), even this
barrier could be crossed for up to half an hour. Strongly contra-
indicated activities (due to electrical short circuits and/or water
aspiration into vent lines), such as swimming in a pool, or
simpler things like taking a bath in a tub became a reality, despite
the dependence on an active VAD. Of course, such wireless
systems can be further improved and adapted to the current con-
tinuous ﬂow pumps used for ventricular support and the same
holds true for the implantable energy storage capacity. However,
there are also very different approaches under investigation like, e.
g. motor-less cardiac compression designs as suggested by P.
Tozzi [13, 14], which are made from electroactive materials allow-
ing for contraction like artiﬁcial muscles. Hence, extra-cardiac
compression devices without direct exposure to the bloodstream
can be designed, potentially eliminating the currently contraindi-
cated withdrawal of anticoagulants in VAD patients.
There are also new indications for cardiopulmonary support
(CPS) and extra-corporeal membrane oxygenation (ECMO) [15].
As everyone knows, the pump-oxygenator was initially devised
by John Gibbon for the treatment of severe pulmonary emboli
after he had witnessed the sad outcome of such an event in a
young patient. The development of ECMO has been rather slow
but steady, and the extracorporeal life support organization
Figure 1: Schematic view of the surgical treatment of atrial ﬁbrillation: the
dotted lines represent the basis of the stapled left atrial appendage, a proced-
ure that is now routinely realized with video-endoscopic techniques.
Figure 2: (A) Schematic view of an implantable LVAD connected to the left ventricle (inﬂow) and the aorta (outﬂow). Implantable VADs made a major contribution
for the indicated out-patient treatment of terminal heart failure. (B) The Lion Heart: a totally implantable LVAD including the pump [47], the motor, the controller,
the compliance chamber with its port for volume adjustment and the smaller internal coil in the right infra-clavicular area. The larger coil on the skin could be
removed for up to half an hour providing unprecedented freedom to the patient including swimming. (C) The CORx device: a miniaturized pump-oxygenator
design with extra-low priming volume on the road to stealth perfusion.
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registry (www.elsonet.org) has shown that this approach was
useful not only for the indicated respiratory, but also for the sup-
posedly contraindicated cardiac failure [16]. One of the remain-
ing problems is the considerable haemodilution due to the
ECMO circuit, which can become a major issue if the latter has
to be changed several times. However, stripped down, integrated
pump-oxygenator designs have been developed (Fig. 2C) with
minimized priming volumes below 400 ml for the entire circuit,
which allow for stealth perfusion [17], i.e. without visible modiﬁ-
cation of the haematocrit. Hence, the theoretically contraindi-
cated mass transfusions in this setting may no longer be
indicated. A different issue is the scavenging of a major part of
the circulating blood volume in the pulmonary circulation in
patients with weak or ﬁbrillating heart, a situation where the
aortic valve does not open, and nothing can be ejected from the
left ventricle. Remote pulmonary artery drainage (Fig. 3A) by
ﬂexible wall-less venous cannulas (Smartcanula LLC, Lausanne,
Switzerland) introduced from the groin through the tricuspid
and pulmonary valves [18] is promising for this scenario. An al-
ternative to this unfamiliar and thus still contraindicated
closed-chest approach, e.g. in hyper-acute rejection of an ortho-
topic heart transplant, may be cardiectomy (Fig. 3B) combined
with a bi-atrial anastomosis [19] and temporary caval stenting
[20]. In addition, there are also an increasing number of indica-
tions for CPS in resuscitation [21], a promising ﬁeld based on
technologies similar to that of ECMO.
CONGENITAL HEART DISEASE
An essential difference between adult cardio-vascular surgery
and paediatric cardio-vascular surgery is the growing organism
in the latter, which implies that repairs that are right today will
probably not be so tomorrow and may be contraindicated.
Hence, there is increasing interest in re-adjustable procedures,
re-adjustable implants, bio-absorbable structures and hybrid
repairs. Although re-dilatable stents are already quite indicated
in current practice, the compensation for growth remains a
major challenge as soon as tube grafts, valve prostheses and
more complex devices are required. Quite some time ago, we
reported growing grafts based on intestinal tissue [22], and
others have worked with extracellular matrix [23] in an experi-
mental setting. However, there are not too many formal indica-
tions with this approach in clinical practice yet. At this time, the
pragmatic approach for extra-cardiac conduits in the growing or-
ganism is to implant a conduit as big as possible, and this
despite the fact that conduit compression may result in valve
leakage, suboptimal ﬂow characteristics, delayed recovery and
earlier conduit failure, problems that make excessive oversizing
contraindicated. Hence, there is an indication for patient-
adjusted conduit conﬁgurations with optimized sizes, taking in
account both the current functional requirements in a given
chest, and the maximally implantable ﬂow reserve based on
geometrical simulations (Fig. 4A), computational ﬂuid dynamics
and preoperative ﬁtting studies in silico and/or in vitro by the
means of rapid prototyping [24].
PULMONARY ARTERY HYPERTENSION
Pulmonary hypertension is a frequent problem in simple and
more complex congenital heart disease. But there are also nu-
merous other situations where cardiac and non-cardiac surgeries
are considered contraindicated because of chronic long-lasting
pulmonary artery hypertension [25]. It has been shown that pul-
monary artery hypertension can be reversed in late referrals of
complex transpositions of the great arteries undergoing progres-
sive pulmonary artery banding (Fig. 4B). For this paediatric appli-
cation, a telemetrically adjustable pulmonary artery band
(Fig. 4C), the so-called FloWatch® (Leman Medical Technologies
SA, Geneva, Switzerland) was developed [26]. It has also been
shown that hypertension-induced sclerosis in the kidney and the
heart could be reversed if the systemic hypertension was con-
trolled by adequate medication [27]. Likewise, it is well known
for severe pulmonary hypertension contraindicating cardiac
transplantation that temporary ventricular assist can result in
reduced pulmonary vascular artery resistance, thus making
Figure 3: (A) Schematic view of trans-femoral decompression of the pulmon-
ary vascular bed with a wall-less cannula during ECMO with ﬁbrillating or
arrested heart resulting in improved perfusion. (B) Peroperative view of cardi-
ectomy with bi-atrial anastomosis and temporary caval stenting in the experi-
mental setting: improved venous drainage can be achieved.
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cardiac transplantation ultimately indicated. Hence, it can be
speculated that pulmonary hypertension currently contraindicat-
ing numerous therapies should also be inﬂuenced under certain
circumstances if appropriate devices for progressive but slow
pulmonary inﬂow reduction, e.g. in the grown-up with un-
corrected congenital heart disease, were made available.
CORONARY ARTERY DISEASE
Coronary artery revascularization remains one of the main activ-
ities in most cardio-vascular surgical programmes [21]. Once
again, the most recent European guidelines on myocardial
Figure 4: (A) Geometrical modelling of an oversized extra-cardiac conduit
between the right ventricle and the pulmonary bifurcation required for size
optimization with regard to intrathoracic space restrictions and growth
reserve by computational ﬂuid dynamics (courtesy D. Berdajs, Lausanne,
Switzerland). (B) Schematic view of an implantable device for incremental
pulmonary artery banding. (C) X-ray showing the FloWatch®, an implantable
device for the remote control of pulmonary artery blood ﬂow designed for
congenital heart disease in the neonatal and infant age group. Adequate
energy transmission for larger patients is not yet available (energy for the step
motor is transmitted by the external controller, and thus larger distances
between the device and the skin currently limit the application).
Figure 5: (A) Schematic view of a sensing stabilizer designed for minimally in-
vasive direct coronary artery bypass and off-pump coronary artery bypass on
the beating heart, a technique providing electric feedback during bypass
surgery without cardiopulmonary bypass. (B) Computational ﬂuid dynamics
(blue = low velocity ﬁelds, red = high velocity ﬁelds) of an optimized end to
side anastomosis for coronary artery revascularization inspired by technical
applications (courtesy C. Oedman, Lausanne, Switzerland).
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revascularization have made the superiority of surgical revascu-
larization in chronic coronary artery disease very clear [28], and
the late results of the so-called all-comer Syntax trial [29] are
even more supporting the recommendations for surgical revas-
cularization. Hence, surgical myocardial revascularization appar-
ently contraindicated in the catheterization lab is, in fact, very
much indicated in the vast majority of patients with chronic mul-
tivessel coronary artery disease. However, coronary artery bypass
grafting (CABG) in patients with very low ejection fraction
remains a major challenge. Several techniques like off-pump
CABG and assisted beating heart surgery both relying on stabili-
zers (Fig. 5A), have been promoted. As an alternative, Tudorache
et al. [30] have shown, in an experimental setting that pedicled
autologous intestinal patches could not only provide contractile
elements to the heart, but nourish it due to the patch vascula-
ture. This approach may also be indicated as a platform for
grafted pluripotent stem cells or cultured contractile tissue, in
order to reconnect them to the bloodstream, even for severely
infarcted territories of the heart, thus turning a contraindication
into an indication.
Standardization of anastomoses in coronary artery bypass
surgery certainly has great potential. In this ﬁeld, there has been
a period of enthusiasm with very broad indications for mechan-
ical anastomoses at the end of the 20th century. Unfortunately,
this enthusiasm has faded due to late occlusions, and thus many
anastomotic connecting devices became contraindicated and
have disappeared. It should be considered that stapling was
introduced in general surgery more than 100 years ago (see
above) and has only relatively recently become the standard for
intestinal resections and anastomoses. In the vascular ﬁeld,
devices avoiding foreign material within the vascular lumen have
already been developed [31]. Optimization of anastomotic con-
ﬁgurations with the help of computational ﬂuid dynamics taking
advantage of the knowledge gained in technical applications can
also provide further insights (Fig. 5B). Hence, writing off mechan-
ical anastomoses seems to be premature, taking into account the
numbers of anastomoses performed in cardio-vascular surgery
under various conditions every day. Particularly in less-easy redo
procedures, the search for quick and reliable mechanical anasto-
moses is certainly indicated. In addition, the potential indications
for glues [32] in the surgical ﬁeld appear to be underexplored
when compared with technical disciplines with similar physical
constraints.
ANEURYSMS
A different challenge is thoracic endovascular aneurysm repair
including the entire aortic arch. Nowadays, open as well as
hybrid solutions (Fig. 6A) without or with transposition of one or
several supra-aortic vessels are standard. A glance at abdominal
aortic aneurysm repair (Fig. 6B) shows that almost 100% of these
cases can be operated with endovascular techniques relying on
fenestrated, branched and chimney grafts (Fig. 6C). It would be
naïve to expect that this development [33] will stop at the dia-
phragm or the left subclavian artery and, therefore, it is a must
Figure 6: (A) Schematic view of a hybrid repair of the thoracic aorta after
Type A aortic dissection combining a Valsalva composite graft, arch repair
with the island technique and a frozen elephant trunk, which can be com-
pleted later on by thoracic endovascular aneurysm repair (TEVAR). (B)
Schematic view of endovascular abdominal aortic aneurism repair (EVAR)
reaching just below the renal arteries and the corresponding sections as it
can be visualized by intravascular ultrasound (IVUS). (C) Supra-renal ﬁxation
of the body of a bifurcated stent-graft for EVAR: the right renal artery is per-
fused through a chimney graft, whereas a stent is placed in an oriﬁce for per-
fusion of the left renal artery (experimental set-up)
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to get actively involved in the development of endovascular
solutions for the arch and the ascending aorta [34]. This even
more so, as the formerly contraindicated transapical access
allows for antegrade insertion of stent-grafts as shown by
L. Niclauss [35], can be considered the royal route to the aortic
arch and the entire aorta and thus will become indicated sooner
or later.
VALVULAR HEART DISEASE
This brings us to the expanding use of catheter valves (Fig. 7A).
Today, the main concern about catheter valves is their durability
[36]. However, once the latter is proven to be acceptable, expo-
nential growth can be expected in this ﬁeld. This development
can be further enhanced by improved device designs, reducing
the contraindications for existing applications, introducing new
indications and developing underexplored routes. To give an
example, a left ventricular aneurysm is considered a contraindi-
cation for transapical implantation of a catheter valve. However,
Ferrari et al. [37] have used precisely this approach for the repair
of an apical left ventricular aneurysm (Fig. 7B) on the occasion
of a catheter valve implantation in an aortic position. Pushing
the frontiers further, we have reported the totally endoscopic
trans-catheter valve implantation relying on pericardium covered
closure devices [38] and by now, there are several devices for
apex closure under investigation. In addition, a right trans-
ventricular, trans-septal route [39] allowed for the transfer of the
access oriﬁce into the low-pressure zone on the right side, with
consecutive ease of sealing. This latter approach does not
require opening the pleural space and may therefore be carried
out under local anaesthesia, even in patients with advanced re-
spiratory problems.
However, the ‘nec plus ultra’ in surgery is NOTES, i.e. Natural
Oriﬁce Transluminmal Endoscopic Surgery, a procedure without
visible scarring. Of course, this can also be applied to cardiothor-
acic surgery, and this despite the fact that there is no natural
oriﬁce leading to the heart. But the umbilicus is not too far
away, and a small incision can be made inside as reported by
Kalejs et al. [40]. For this purpose, a channel was developed from
the umbilicus to the pericardial sac behind the processus
xyphoides using a saphenous-vein-harvesting device. Then, the
heart was punctured at the apex, and a guide-wire was intro-
duced for implantation of the catheter valve. Although not indi-
cated yet, the challenge of this procedure, which is less how to
get in there, but much more how to get out of there, can be
solved with a plug (Fig. 7C)—as usual, I might say.
Valve repair certainly dominates the treatment of mitral valves
in Europe. Hence, it comes as no surprise that also the approach
for trans-catheter mitral valve therapies has been dominated by
repair techniques [41]. Nevertheless, catheter valves are also in-
creasingly being used for the mitral position, even if the initial
steps are valve-in-valve procedures for degenerated bioprosth-
eses [42] and valve-in-rings for recurrent regurgitation [43], thus
taking advantage of the known geometry for the attachment of
the new implant. This brings us to mechanical issues and the
future indications for mechanical heart valve prostheses (Fig. 8A),
which still require anticoagulation with warfarin and the like—
drug therapies with inherent complications on their own, in add-
ition to the lack of comfort due to the life-long blood analyses,
which are required for dose adjustment. The new oral anticoagu-
lants not requiring regular lab work are already changing the
Figure 7: (A) Schematic view of a catheter valve in the aortic position with
annular and ascending aortic ﬁxation. (B) Computed tomography scan after
transapical aortic valve implantation (TAVI) through an apical aneurysm,
which was repaired at this occasion: a contraindication becoming an indica-
tion [37]. (C) NOTES for cardiac valve implantation: a trans-umbilical route
was developed with an endoscopic saphenous-vein-harvesting system for
TAVI. Cardiac access closure was realized with an occluder [40].
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ﬁeld in the prophylaxis of thrombo-embolic events. It does not
take in-depth analyses to predict that once the safety of these
new anticoagulant drugs in conjunction with mechanical heart
valves, i.e. in the aortic position, is proven, a major shift from the
failing biological heart valve prosthesis [44] back towards the
much more reliable mechanical heart valve prosthesis may
become indicated.
OUTLOOK
Robotic surgery has not yet been identiﬁed as being widely indi-
cated in routine thoracic and cardio-vascular surgery. There are
a number of reasons for this, including the fact that the beating
heart does not make it easier compared with similar targets in
other surgical disciplines. However, it is possible to operate suc-
cessfully within the working heart using robotic telemanipulators
with multiple degrees of freedom. When we explored this ap-
proach some time ago [45] in order to realize procedures within
the working heart that cannot be performed with traditional
means (Fig. 8B), we found two essential issues: instrumentation
and visualization (Fig. 8C). The latter problem has since been
addressed with real-time three-dimensional echocardiography
[46] and thus conﬁrms the statement that ‘the solution to pro-
blems with technology is more technology’ (personal communi-
cation by Li-Chien Hsu, Mission Viejo, CA, USA). On the
contrary, there is also another concept promising success in the
future development of thoracic and cardio-vascular surgery like
the position accorded to architecture by John Pawson, London,
UK, which seems very apt: ‘The minimum could be deﬁned as
the perfection that an artefact (suggestion by LvS : a surgical
technique) achieves when it is no longer possible to improve it
by subtraction’.
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